首页> 外文OA文献 >The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions*
【2h】

The Tyrosine 343 Residue of Nucleophosmin (NPM)-Anaplastic Lymphoma Kinase (ALK) Is Important for Its Interaction with SHP1, a Cytoplasmic Tyrosine Phosphatase with Tumor Suppressor Functions*

机译:核糖蛋白(NPM)-间变性淋巴瘤激酶(ALK)的酪氨酸343残基对于与SHP1相互作用具有重要意义,SHP1是具有肿瘤抑制功能的细胞质酪氨酸磷酸酶。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The cytoplasmic tyrosine phosphatase SHP1 has been shown to inhibit the oncogenic fusion protein nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK), and loss of SHP1 contributes to NPM-ALK-mediated tumorigenesis. In this study, we aimed to further understand how SHP1 interacts and regulates NPM-ALK. We employed an in vitro model in which GP293 cells were transfected with various combinations of NPM-ALK (or mutants) and SHP1 (or mutants) expression vectors. We found that SHP1 co-immunoprecipitated with NPM-ALK, but not the enzymatically inactive NPM-ALKK210R mutant, or the mutant in which all three functionally important tyrosine residues (namely, Tyr338, Tyr342, and Tyr343) in the kinase activation loop (KAL) of ALK were mutated. Interestingly, whereas mutation of Tyr338 or Tyr342 did not result in any substantial change in the NPM-ALK/SHP1 binding (assessed by co-immunoprecipitation), mutation of Tyr343 abrogated this interaction. Furthermore, the NPM-ALK/SHP1 binding was readily detectable when each of the remaining 8 tyrosine residues known to be phosphorylated were mutated. Although the expression of SHP1 effectively reduced the level of tyrosine phosphorylation of NPM-ALK, it did not affect that of the NPM-ALKY343F mutant. In soft agar clonogenic assay, SHP1 expression significantly reduced the tumorigenicity of NPM-ALK but not that of NPM-ALKY343F. In conclusion, we identified Tyr343 of NPM-ALK as the crucial site for mediating the NPM-ALK/SHP1 interaction. Our results also support the notion that the tumor suppressor effects of SHP1 on NPM-ALK are dependent on its ability to bind to this oncogenic protein.
机译:已显示胞质酪氨酸磷酸酶SHP1抑制致癌融合蛋白核蛋白(NPM)-间变性淋巴瘤激酶(ALK),而SHP1的丧失则有助于NPM-ALK介导的肿瘤发生。在这项研究中,我们旨在进一步了解SHP1如何相互作用和调节NPM-ALK。我们采用了体外模型,其中GP293细胞被NPM-ALK(或突变体)和SHP1(或突变体)表达载体的各种组合转染。我们发现SHP1与NPM-ALK共同免疫沉淀,但没有酶促失活的NPM-ALKK210R突变体,或者在激酶激活环(KAL)中具有所有三个功能重要的酪氨酸残基(即Tyr338,Tyr342和Tyr343)的突变体)的ALK被突变。有趣的是,虽然Tyr338或Tyr342的突变并未导致NPM-ALK / SHP1结合的任何实质性变化(通过免疫共沉淀评估),但Tyr343的突变却消除了这种相互作用。此外,当已知磷酸化的其余8个酪氨酸残基中的每一个都发生突变时,很容易检测到NPM-ALK / SHP1结合。尽管SHP1的表达有效降低了NPM-ALK的酪氨酸磷酸化水平,但它并不影响NPM-ALKY343F突变体的酪氨酸磷酸化水平。在软琼脂克隆形成测定中,SHP1表达显着降低了NPM-ALK的致瘤性,但没有降低NPM-ALKY343F的致瘤性。总之,我们确定NPM-ALK的Tyr343是介导NPM-ALK / SHP1相互作用的关键部位。我们的研究结果也支持以下观点:SHP1对NPM-ALK的抑癌作用取决于其与该致癌蛋白结合的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号